TGFB1 and breast cancer: The functional interplay between CAFs and neutrophils extends beyond chemotaxis; in breast cancer models, fibroblast‐derived IL‐33 activates neutrophil ST2 receptors, driving IL‐10/TGF‐β production that polarizes Th2‐type immunity [167].